It represents information about percentage of licensor royalty patent grant.

No definition available.

Name:	inmb_PercentageOfLicensorRoyaltyPatentGrant
Namespace Prefix:	inmb_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

It represents information about percentage of net sales to pay royalties.

+ References

No definition available.

+ Details

Name:	inmb_PercentageOfNetSalesToPayRoyalties
Namespace Prefix:	inmb_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix:	us-gaap_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

+ Details

Name:	us-gaap_CommonStockSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_CommonStockSharesSubscriptions
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Including the current and noncurrent portions, carrying value as of the balance sheet date of long-term unsecured obligations issued by corporations and other borrowers to investors (with maturities initially due after one year or beyond the operating cycle if longer).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.16)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.16)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20,22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_LongtermCommercialPaperCurrentAndNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

No definition available.

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=inmb_InkmuneLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=inmb_UniversityOfPittsburgLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	inmb_CommercialSaleAxis=inmb_FirstCommercialSaleOfEachYearTwoZeroEighteenToTwoZeroTwentyTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=inmb_AnnualMaintenanceFeesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	inmb_CommercialSaleAxis=inmb_SecondCommercialSaleOfEachYearTwoZeroTwentyThreeToTwoZeroTwentyFourMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	inmb_CommercialSaleAxis=inmb_AnnuallyCommercialSaleThereafterMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=inmb_ImmuneVenturesToInmuneBioMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	inmb_MilestonePaymentsAxis=inmb_MilestonePaymentPhaseOneInitiationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

RESEARCH AND DEVELOPMENT ACTIVITY (Detail Textuals 1) - USD ($)		12 Months Ended
	Oct. 03, 2017	Dec. 31, 2018	Dec. 31, 2017	Oct. 29, 2015
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Common stock, par value (in dollars per share)		$ 0.001	$ 0.001
Common stock issued (in shares)		8,719,441	8,319,441
INKmune License Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Percentage of licensor royalty patent grant				1.00%
University of Pittsburg License Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Value of common stock issue	$ 162,634
Common stock, par value (in dollars per share)	$ 7.71
Common stock issued (in shares)	21,094
Percentage of net sales to pay royalties	2.50%
University of Pittsburg License Agreement \| June 26 of each year 2018-2022 \| Annual maintenance fees
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Long-term Commercial Paper		$ 5,000
University of Pittsburg License Agreement \| June 26 of each year 2023-2024 \| Annual maintenance fees
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Long-term Commercial Paper		10,000
University of Pittsburg License Agreement \| June 26 of each year 2025 until first commercial sale \| Annual maintenance fees
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Long-term Commercial Paper		25,000
Immune Ventures to INmune Bio ("Licensee"), ("PITT Agreement"). \| Each Phase I initiation
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition, Milestone Method, Revenue Recognized		$ 50,000